Optimally tolerated dose of lapatinib in combinationwith docetaxel plus trastuzumab in first-line treatmentof HER2-positive metastatic breast cancer

Annals of Oncology

Volumn 24, Issue 8, 2013, Pages 2005-2011

  Crown, John ^a   Kennedy, M J ^a   Tresca, P ^b   Marty, M ^c   Espie, M ^c   Burris, H A ^d   DeSilvio, M ^e   Lau, M R ^f   Kothari, D ^f   Koch, K M ^e   Dieras V ^b  

^a All Ireland Cooperative Oncology Research Group   (Ireland)

^b INSTITUT CURIE   (France)

^c SAINT LOUIS HOSPITAL   (France)

^d SARAH CANNON RESEARCH INSTITUTE   (United States)

^e GLAXOSMITHKLINE   (United States)

^f GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Docetaxel; HER2 ERBB2; lapatinib; Metastatic breast cancer; Trastuzumab; Tyrosine kinase inhibitor

Indexed keywords

DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GRANULOCYTE COLONY STIMULATING FACTOR; LAPATINIB; TRASTUZUMAB;

ADULT; AGED; ALOPECIA; ARTHRALGIA; ARTICLE; ASTHENIA; BONE SCINTISCANNING; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CLINICAL EVALUATION; COLITIS; COUGHING; DEHYDRATION; DIARRHEA; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; EPISTAXIS; FATIGUE; FEBRILE NEUTROPENIA; GENERAL CONDITION DETERIORATION; HEADACHE; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HUMAN; HYPERKALEMIA; HYPONATREMIA; HYPOTENSION; KIDNEY FAILURE; LEUKOPENIA; LOADING DRUG DOSE; LUNG FIBROSIS; MAJOR CLINICAL STUDY; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAIL DISEASE; NAUSEA; NEUTROPENIA; ONYCHOLYSIS; OPTIMAL DRUG DOSE; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PRIMARY HEALTH CARE; PRIORITY JOURNAL; RHINORRHEA; SEPSIS; SIDE EFFECT; TREATMENT DURATION; VOMITING;

DOCETAXEL; HER2/ERBB2; LAPATINIB; METASTATIC BREAST CANCER; TRASTUZUMAB; TYROSINE KINASE INHIBITOR;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM METASTASIS; QUINAZOLINES; RECEPTOR, ERBB-2; RECOMBINANT PROTEINS; TAXOIDS; YOUNG ADULT;

EID: 84881237946     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt222     Document Type: Article

References (19)

1. Press MF, Bernstein L, Thomas PA et al. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in nodenegative breast carcinomas. J Clin Oncol 1997; 15: 2894-2904.
2. Slamon DJ, Godolphin W, Jones LA et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707-712.
3. Marty M, Cognetti F, Maraninchi D et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 2005; 23: 4265-4274.
4. Gullo G, Zuradelli M, Sclafani F et al. Durable complete response following chemotherapy and trastuzumab for metastatic HER2-positive breast cancer. Ann Oncol 2012; 23: 2204-2205.
5. Konecny GE, Pegram MD, Venkatesan N et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 2006; 66: 1630-1639.
6. Geyer CE, Forster J, Lindquist D et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006; 355: 2733-2743.
7. O'Brien NA, Browne BC, Chow L et al. Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib. Mol Cancer Ther 2010; 9: 1489-1502.
8. O'Donovan N, Byrne AT, O'Connor AE et al. Synergistic interaction between trastuzumab and EGFR/HER-2 tyrosine kinase inhibitors in HER-2 positive breast cancer cells. Invest New Drugs 2011; 29: 752-759.
9. Blackwell KL, Burstein HJ, Storniolo AM et al. Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumabrefractory metastatic breast cancer. J Clin Oncol 2010; 28: 1124-1130.
10. Blackwell KL, Burstein HJ, Storniolo AM et al. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. J Clin Oncol 2012; 30: 2585-2592.
11. Baselga J, Bradbury I, Eidtmann H et al. on behalf of the NeoALLTO Study Team. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 2012; 379: 633-640.
12. Robidoux A, Tang G, Rastogi P et al. Evaluation of lapatinib as a component of neoadjuvant therapy for HER2+ operable breast cancer: NSABP protocol B-41 [abstract]. J Clin Oncol 2012; 30: Abstract LBA506.
13. Chan S, Friedrichs K, Noel D et al. for the 303 Study Group. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 1999; 17: 2341-2354.
14. Pegram MD, Konecny GE, O'Callaghan C et al. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst 2004; 96: 739-749. original articles Annals of Oncology
15. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92: 205-216.
16. LoRusso PM, Jones SF, Koch KM et al. Phase I and pharmacokinetic study of lapatinib and docetaxel in patients with advanced cancer. J Clin Oncol 2008; 26: 3051-3056.
17. Dawood S, Broglio K, Buzdar AU et al. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol 2010; 28: 92-98.
18. Morohashi S, Odagiri H, Morohashi H et al. Complete remission of recurrent breast cancer with multiple liver metastases after oral capecitabine and injected trastuzumab. Breast Cancer 2007; 14: 297-301.
19. Valero V, Forbes J, Pegram MD et al. Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens. J Clin Oncol 2011; 29: 149-156.